

Tambahan Indikasi yang diluluskan dalam Mesyuarat PBKD 402, 7 November 2024

Products approved for additional indication (DCA 402 – 7 November 2024)

No.	Product [Active Ingredient]	Additional Indication	Product Registration Holder (PRH)
1.	<p>Olumiant 2mg Film-Coated Tablet [Baricitinib 2mg]</p> <p>Olumiant 4mg Film-Coated Tablet [Baricitinib 4mg]</p>	<p>INDICATION :</p> <p>Atopic Dermatitis</p> <p>Baricitinib is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy.</p> <p>POSODOLOGY :</p> <p>Atopic dermatitis</p> <p><u>Children and adolescents (2 years of age and older)</u></p> <p>The recommended dose of baricitinib is 4 mg once daily for patients weighing 30 kg or more. For patients weighing 10 kg to less than 30 kg, the recommended dose is 2 mg once daily.</p> <p>Baricitinib can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used, but should be reserved for sensitive areas only, such as the face, neck, intertriginous and genital areas.</p> <p>Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit after 8 weeks of treatment.</p>	<p>ZUELLIG PHARMA SDN. BHD.</p> <p>No. 15, Persiaran Pasak Bumi, Sek. U8, Perindustrian Bukit Jelutong, 40150 Shah Alam, Selangor.</p>